What is the Incyte Corporation stock price forecast?

Incyte Corporation is currently trading at $99.75. View real-time AI analysis on Alpha Lenz.

What is Incyte Corporation insider trading activity?

View the latest insider trading data for Incyte Corporation on Alpha Lenz.

What is Incyte Corporation's P/E ratio?

Incyte Corporation's P/E ratio is 15.1.

Incyte Corporation

NASDAQ · INCY

$99.75-2.23(-2.19%)Pre-market

Ask about Incyte Corporation's future dividend policy...

Alpha Chat Insight

“Incyte Corporation trades at a P/E of 15.1 (fair value) with strong ROE of 29.9%. 3Y revenue CAGR of 14.8% highlights clear growth momentum.”

Ask for details →

Company Overview

Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.

CEOMr. Herve Hoppenot

Websitehttps://www.incyte.com

SectorHealthcare

IndustryBiotechnology

Employees2,617

Company Statistics

FY 2025

Profile

$19.47BMarket Cap

$5.14BRevenue

0.00Shares Out

2,617Employees

Margins

92.76%Gross

30.47%EBITDA

26.12%Operating

32.37%Pre-Tax

25.03%Net

Valuation

15.13P/E

3.77P/B

3.79EV/Sales

10.48EV/EBITDA

14.64P/FCF

Growth (CAGR)

14.84%Rev 3Yr

14.03%Rev 5Yr

31.42%Op Inc 3Yr

N/AOp Inc 5Yr

55.73%Net Inc 3Yr

N/ANet Inc 5Yr

Returns

20.75%ROA

29.87%ROE

26.88%ROIC

Financial Health

$3.10BCash & Cash Equivalents

$-1.31BNet Debt

34.65%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Incyte Corporation trades at a P/E of 15.1 (fair value) with strong ROE of 29.9%. 3Y revenue CAGR of 14.8% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Incyte Corporation (ticker: INCY) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 2,617 employees. Market cap is $19.5B.

The current price is $99.75 with a P/E ratio of 15.13x and P/B of 3.77x.

ROE is 29.87% and operating margin is 26.12%. Annual revenue is $5.1B.